Glutamine energy substrate anaplerosis increases bone density in the Pah\textsuperscript{enu2} classical PKU mouse in the absence of phenylalanine restriction

Steven F. Dobrowolski\textsuperscript{1} | Yu Leng Phua\textsuperscript{2} | Irina L. Tourkova\textsuperscript{1,3} | Cayla Sudano\textsuperscript{1} | Jerry Vockley\textsuperscript{2} | Quitterie C. Larrouture\textsuperscript{1,3} | Harry C. Blair\textsuperscript{1,3}

\textsuperscript{1}Department of Pathology, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA
\textsuperscript{2}Division of Medical Genetics and Genomics, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
\textsuperscript{3}Pittsburgh Veteran’s Affairs Medical Center, Pittsburgh, Pennsylvania, USA

Abstract

Osteopenia is an under-investigated clinical presentation of phenylalanine hydroxylase (PAH)-deficient phenylketonuria (PKU). While osteopenia is not fully penetrant in human PKU, the Pah\textsuperscript{enu2} mouse is universally osteopenic and ideal to study the phenotype. We determined Pah\textsuperscript{enu2} mesenchymal stem cells (MSCs) are developmentally impaired in the osteoblast lineage. Moreover, we determined energy dysregulation and oxidative stress contribute to the osteoblast developmental deficit. The MSC preferred substrate glutamine (Gln) was applied to enhance energy homeostasis. In vitro Pah\textsuperscript{enu2} MSCs, in the context of 1200 \( \mu \)M Phe, respond to Gln with increased in situ alkaline phosphatase activity indicating augmented osteoblast differentiation. Oximetry applied to Pah\textsuperscript{enu2} MSCs in osteoblast differentiation show Gln energy substrate increases oxygen consumption, specifically maximum respiration and respiratory reserve. For 60 days post-weaning, Pah\textsuperscript{enu2} animals received either no intervention (standard lab chow), amino acid defined chow maintaining plasma Phe at \(<200 \mu\text{M}, or standard lab chow where ad libitum water was a 2\% Gln solution. Bone density was assessed by microcomputed tomography and bone growth assessed by dye labeling. Bone density and dye labeling in Phe-restricted Pah\textsuperscript{enu2} was indistinguishable from untreated Pah\textsuperscript{enu2}. Gln energy substrate provided to Pah\textsuperscript{enu2}, in the context of uncontrolled hyperphenylalaninemia, present increased bone density and dye labeling. These data provide further evidence that Pah\textsuperscript{enu2} MSCs experience a secondary energy deficit that is responsive both in vitro and in vivo to Gln energy substrate and independent of hyperphenylalaninemia. Energy support may have effect to treat human PKU osteopenia and elements of PKU neurologic disease resistant to standard of care systemic Phe reduction. Glutamine energy substrate anaplerosis increased Pah\textsuperscript{enu2} bone density and improved in vitro MSC
function in the context of hyperphenylalaninemia in the classical PKU range.

KEYWORDS
glutamine, osteopenia, oxidative phosphorylation, Pahenu2, phenylketonuria

1 INTRODUCTION

Phenylalanine hydroxylase (PAH)-deficient PKU is a treatable inborn error of metabolism where dietary Phe restriction is the principal intervention. Early intervention, enabled by newborn screening, disallows neurologic devastation yet cognitive deficit, executive function deficit, neuropsychiatric phenotypes, and osteopenia remain common among treated patients.

Phenylketonuria (PKU) osteopenia was identified in the 1960s and clinical description of osteopenic PKU patients is extensive. Similar reduction in total body bone mineral density is observed. Equivalently low bone mineral density occurs in therapy noncompliant patients.

Pathophysiological mechanisms of PKU bone disease remain ambiguous. The bone phenotype was originally attributed to diet therapy where by an undefined mechanism, bioavailability of calcium, phosphorous, and other bone-forming material were reduced; however, this is poorly supported as osteopenia is recognized in patients that never received diet therapy and young patients following short-term therapy. Several studies find no correlation between hyperphenylalaninemia and bone disease; others show a negative correlation between hyperphenylalaninemia and bone disease. Biochemical ambiguity does not end with Phe homeostasis as representation of bone formation markers, bone resorption markers, and other metrics related to bone provide no means to inform osteopenia risk.

Phenylketonuria osteopenia has knowledge gaps as investigation is descriptive and pathophysiology is largely un-investigated. While the bone phenotype is not fully penetrant in humans, osteopenia is universal in the Pahenu2 mouse model of classical PKU. Our previous investigations of Pahenu2 osteopenia identified a mesenchymal stem cell (MSC) developmental defect involving energy deficit and oxidative stress. These investigations were the first to assess bone development as a participatory element in the pathology of the PKU osteopenia. Here, we apply the MSC preferred energy substrate glutamine to in vitro MSC differentiation and mitochondrial oxygen consumption. Gln enhances MSC osteoblast development and increases mitochondrial oxygen consumption. In vivo a post-weaning Gln regimen increased Pahenu2 bone density. Moreover, augmentation of in vitro MSC metrics and in vivo bone density was achieved within the context of hyperphenylalaninemia in the classical range. Energy repletion provides an alternative intervention to treat Pahenu2 osteopenia acting independent of systemic Phe homeostasis.

2 METHODS

2.1 Pahenu2 and control animals

Pahenu2 and C57bl/6 were propagated at the Rangos Research Center animal facility at Children’s Hospital of Pittsburgh with an approved protocol. Experimental and control animals were generated matings heterozygous females and heterozygous males. Offspring were genotyped as described. Alternative homozygous genotypes (experimental enu2/enu2, control wt/wt) were used in experimental cohorts. After weaning (day of life 21), Pahenu2 animals were provided one of the following diets. 1. Standard mouse chow; 2. standard mouse chow where the ad libitum water supply was a 2% Gln solution; 3. Phe-free amino acid defined chow with Phe supplemented in drinking water (0.35 g/L). Standard chow and standard chow plus 2% Gln maintain Pahenu2 plasma of 2000 μM in males and 2200 μM in females. Phe-free amino acid defined chow produces Pahenu2 plasma Phe of ~200 μM. Animals provided dietary Phe restriction were utilized in vivo histomorphometry studies. Owing to Gln aqueous instability, over the 60-day post-weaning regimen, a freshly dissolved 2% Gln solution was provided each Monday, Wednesday, and Friday. Control (wt/wt)
littermates were provided standard mouse chow. Experiments used animals in the fed state. Animals (control, Pah\textsuperscript{enu2}) were sacrificed by CO\textsubscript{2} asphyxiation, at 2–3 months of age.

2.2 Mesenchymal stem cell culture and osteoblast differentiation

Experimental and control cohorts contained at least four animals (equal male/female representation). MSCs were prepared from 2- to 3-month animals (control, Pah\textsuperscript{enu2}) as described\textsuperscript{23–25}. Briefly, bone marrow was flushed (RPMI-1640 10% fetal calf serum) with an insulin syringe from the femur and tibia. Aspirate was plated for \~18 h at 37°C to remove rapidly attaching fibroblast-like cells. Non-adherent cells were re-plated at 2 × 10\textsuperscript{6} cells/cm\textsuperscript{2}. After 72 h non-adherent cells were discarded and adherent cells provided MSC proliferation medium (MesenCult Proliferation media, Stemcell Technologies). Cultures were expanded and passage 4–7 cells were used in osteoblast differentiation. Osteogenic differentiation applied for 14 or 21 days applied media containing 35 \(\mu\)g/ml L-ascorbic acid, 10 mM \(\beta\)-glycerophosphate, 10\(\mu\)M adrenocorticotropic hormone, 10\(\mu\)M 1\(\alpha\), 25-dihydroxyvitamin D3, and 0.5 mM CaCl\(_2\).\textsuperscript{31} MSC osteoblast differentiation media in control Pah\textsuperscript{enu2} cultures is supplemented with Phe to 1200 \(\mu\)M. Pah\textsuperscript{enu2} MSC cultures receiving Gln energy substrate includes 1% Gln and Phe to 1200 \(\mu\)M. Over the course of differentiation, media were replaced every Monday, Wednesday, and Friday. MSC osteoblast differentiation was assessed by in situ alkaline phosphatase activity and mineralization. In situ alkaline phosphatase activity used 0.01% napthol AS-MX substrate and fast blue product visualization as described\textsuperscript{23–25}. Visualizing mineralization used von Kossa silver staining as described.\textsuperscript{23–25} Densitometry analysis was performed after converting the image to grayscale, inverted, and the mean white area was measured with ImageJ software.

2.3 Oximetry of MSC cultures in osteoblast differentiation

Proliferating Pah\textsuperscript{enu2} and control MSCs (40 000 cells) were plated in 96-well Seahorse oximetry plates. At confluence, osteoblast differentiation was induced as above. Experimental Pah\textsuperscript{enu2} cultures were provided media including 1% Gln. On day 14 post-induction, 20 h prior to assessment, differentiating MSCs were washed and unbuffered media provided. Experimental conditions (supplemental Phe, Gln) were maintained in unbuffered media. Assessment utilized the Seahorse Mito Stress Test that applies oligomycin, carbonyl cyanide-4-phenylhydrazone (FCCP), 2-deoxy-glucose, and rotenone/antimycin to determine basal respiration, maximal respiration, ATP production, and spare capacity.\textsuperscript{23,32,33} During assessment, each experimental and control condition utilized eight replicate wells. Data analysis is as described using Graph pad software and unpaired T-test.\textsuperscript{23,32,33}
2.4 Microcomputed tomography and dye labeling

Experimental (Pah^{enu2} Phe restricted diet, Pah^{enu2} Gln energy substrate diet) and control (C57bl/6, unmanaged Pah^{enu2}) animal cohorts (minimum 6 animals, equal male vs. female representation) were sacrificed 2 months post-weaning. Trabecular bone analysis applied microcomputed tomography as described in a blinded manner. Briefly, fixed lumbar vertebrae, were scanned in 70% ethanol at 6-\mu m resolution with a 0.25-mm aluminum filter; voltage and current were set at 69 kV and 100 \mu A. Image reconstruction utilized Nrecon and InstaRecon software. Cross sectional images used

| (A) Percent Bone Volume | (B) Bone Surface Density |
|------------------------|-------------------------|
| **ns**                 | *                       |
| BV/TV (%)              | BS/TV (mm⁻¹)            |
| Control                | PKU                     |
| PKU                    | PKU PHE-free            |
| PKU PHE-free           | PKU +Gln                |

| (C) Trabecular Number  | (D) Total Porosity      |
|-----------------------|-------------------------|
| **ns**                | *                       |
| Tb.N, mm⁻¹            | Po(tot), %              |
| Control               | PKU                     |
| PKU                   | PKU PHE-free            |
| PKU PHE-free          | PKU +Gln                |

| (E) Calcien and Xylenol Orange Labeling |
|----------------------------------------|
| **ns**                                 |
| Proportion Labeled                     |
| Control                                |
| PKU                                    |
| PKU PHE-free                           |
| PKU +Gln                               |

**FIGURE 3** Increased in vivo Pah^{enu2} bone density and appositional growth with Gln energy substrate anaplerosis in uncontrolled hyperphenylalaninemia **FIGURE 3**. Static and dynamic histomorphometry of unmanaged Pah^{enu2} (plasma Phe 2000–2200 \mu M), Phe-restricted Pah^{enu2} (plasma Phe 200\mu M) and Pah^{enu2} provided Gln energy substrate (plasma Phe 2000–2200 \mu M). Control animals are background strain C57bl/6 littermates. All cohorts have a minimum of six animals (3 male and 3 female). Static histomorphometry metrics determined in third or fourth lumbar vertebrae: (A) Percent bone volume, (B) Bone surface density, (C) Trabecular number, (D) Total porosity. Dynamic histomorphometry appositional dye labeling determined in third lumbar vertebrae: 3E In vivo calcien and xylenol orange labeling. * p ≤ 0.05; ** p ≤ 0.01; **** p ≤ 0.0001
Dataviewer software. Quantitative analysis assessed a 1.2-mm region at the midpoint of the fourth lumbar vertebrae. Determined were bone volume/total volume, bone surface density, trabecular number, and total porosity. Data represent that of the entire cohort (experimental, control) not parsed by sex. Dynamic histomorphometry applied 7 days and 2 days prior to sacrifice intra-peritoneal injection of calcein (20 μg/g mouse weight) and xylenol orange (80 μg/g mouse weight), respectively. Cutting undecalcified 7 μm frozen sections applied tape means. Measurement of dye-labeled surface was performed as described.24

3 | RESULTS

3.1 | In the context of hyperphenylalaninemia, Gln energy substrate increased Pah<sup>enu2</sup> in situ alkaline phosphatase activity

Figure 1 provides staining of in situ alkaline phosphatase activity. As previously reported, Pah<sup>enu2</sup> MSCs in osteoblast differentiation have decreased alkaline phosphatase activity compared to C57bl/6. Pah<sup>enu2</sup> MSCs provided Gln energy support demonstrate a statistically significant increase in in situ alkaline phosphatase activity. Mineralization did not increase with Gln energy substrate (data not shown).

3.2 | In the context of hyperphenylalaninemia, Gln energy substrate increased Pah<sup>enu2</sup> MSC oxygen consumption in osteoblast differentiation

Figure 2 oximetry applied the Seahorse Mito Stress Test to MSCs following 14 days of osteoblast differentiation. Basal oxygen consumption and ATP production are equivalent between C57bl/6, Pah<sup>enu2</sup>, and Pah<sup>enu2</sup> provided Gln energy substrate. Maximum respiration and spare capacity of Pah<sup>enu2</sup> and Pah<sup>enu2</sup> with 1% Gln are both less than that of C57bl/6 controls. However, Gln energy substrate provided Pah<sup>enu2</sup> MSCs statistically significant increases to both maximum respiration and spare capacity.

3.3 | In vivo Gln energy substrate increases Pah<sup>enu2</sup> bone density in uncontrolled hyperphenylalaninemia

In vivo assessment provided Pah<sup>enu2</sup> Gln energy substrate from weaning (day of life 21) continuously for the following 60 days ad libitum as a 2% Gln solution in the water supply. These animals otherwise received normal chow causing unregulated Phe homeostasis of ~2000 in males and 2200 μM in females. For comparison, a separate Pah<sup>enu2</sup> cohort was provided a Phe restricted diet, maintaining blood Phe of ~2200 μM. Microcomputed tomography, assessing the fourth and fifth lumbar vertebrae, determined bone density of untreated Pah<sup>enu2</sup> and Phe-restricted Pah<sup>enu2</sup> is identical. All metrics (bone volume/total volume, bone surface density, trabecular number, and total porosity) are indistinguishable and significantly less than unaffected control littersmates. Pah<sup>enu2</sup> provided Gln energy substrate anaplerosis, in the context of unrestricted Phe homeostasis, show improved static histomorphometry metrics and improved dye labeling. Bone density improved among Phe unrestricted Pah<sup>enu2</sup> receiving Gln energy substrate anaplerosis. Similarly, calcein and xylenol orange dye labeling was identical between control Pah<sup>enu2</sup> and Phe-restricted Pah<sup>enu2</sup>. Gln substrate increased dye labeling to equivalence with unaffected littersmates.

4 | DISCUSSION

Osteopenia is an under-investigated phenotype in PAH-deficient PKU and pathophysiology remains ill-defined. PKU clinical phenotypes occur in brain and bone. As neither tissue express the PAH gene nor hydroxylate Phe, clinical phenotypes arise from secondary effect of biochemical dysregulation. The universally osteopenic Pah<sup>enu2</sup> mouse is an ideal model to study osteopenia as the phenotype is not fully penetrant in patients. We determine Pah<sup>enu2</sup> MSCs are deficient in osteoblast differentiation where energy deficit and oxidative stress are contributing factors.23–25 In the context of hyperphenylalaninemia, the MSC preferred energy substrate Gln increased in vitro alkaline phosphatase activity (a measure of osteoblast differentiation) and mitochondrial oxygen consumption (a measure of oxidative energy production). In vivo Gln energy substrate improved bone density concurrent to unregulated hyperphenylalaninemia.

While resting and proliferating MSCs are glycolytic, those in the course of osteoblast differentiation require oxidative phosphorylation. Respirometry applied to mitochondria from Pah<sup>enu2</sup> MSC during osteoblast differentiation, showed an attenuated complex 1 response to pyruvate substrate; however, complex 1 response to glutamate (Glu) substrate was similar to controls.23 Respirometry in Pah<sup>enu2</sup> brain tissue mitochondria showed similar attenuated response to pyruvate substrate.34 Pyruvate enters mitochondria through voltage dependent anion channels. The Phe catabolite phenylpyruvate is structurally similar to pyruvate and a recognized inhibitor of
pyruvate mitochondrial transport. Pyruvate transport inhibition reduces acetyl-CoA that drives Kreb cycle processivity and creation of reducing equivalents for oxidative phosphorylation. On the plasma membrane, MSCs express SLC1A5 high-affinity Gln transporter. Cytosolic glutaminase converts Gln to Glu. Two related proteins, the mitochondrial glutamate carriers GC1 (SLC25A22) and GC2 (SLC25A18) transport Glu into the mitochondria, where it is converted to alpha-ketoglutarate distally repleting the Kreb cycle. We posit Gln energy substrate dria, where it is converted to alpha-ketoglutarate distally repleting the Kreb cycle. We posits Gln energy substrate increases Pahμ2 bone density by alternative pathway Kreb cycle repletion circumventing phenylpyruvate inhibition of pyruvate transport. Gln up-regulates energy homeostasis enabling osteogenesis (Figures 1-3). Augmented MSC function and increased bone density within the context hyperphenylalaninemia is a consequence of alternative energy pathway utilization. Moreover, realizing increased bone density in uncontrolled hyperphenylalaninemia strongly argues against causation by asymmetric amino acid transport through the LAT1 (SLC7A5 gene product) transporter.

Increased bone density is the first physiologically quantifiable PKU intervention response occurring independent of systemic Phe management. As most adolescent/adult PKU patients are therapy noncompliant, Gln energy support may provide a means to treat osteopenic patients unwilling/unable to engage systemic Phe reduction. Further, even more importantly, these data suggest energy deficit may contribute to PKU neurologic phenotypes. Even that small minority of adult/adolescent PKU patients that remain compliant to Phe reduction therapy present cognitive decline, executive function deficit, and other late onset neurologic phenotypes. Should energy deficit contribute to neurologic disease, energy support, be it Gln or other alternative pathway substrates, may provide an under-appreciated intervention opportunity.

Literature Cited

**REFERENCES**

1. Guthrie R, Sussi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. *Pediatrics*. 1963;32:318-322.
2. Fölling A Uber Ausscheidung von Phenylbrenztraubensaure in den Harn als Stoffwechselanomalie in Verbindung mit Imbezillitat. *Hoppe Seylers Z Physiol Chem*. 1934;277(169):169-181.
3. Jervis GA. Phenylpyruvic oligophrenia: deficiency of phenylalanine oxidizing system. *Proc Soc Exp Biol Med*. 1953;82:514-515.
4. Bickel H. Influence of phenylalanine intake on phenylketonuria. *Lancet*. 1953;265:812-813.
5. MacCreary RA. Admissions of phenylketonuric patients to residential institutions before and after screening programs of the newborn infant. *J Pediatr*. 1974;85:383-385.
6. Garcia MI, Araya G, Coo S, Waisbren SE, de la Parra A. Treatment adherence during childhood in individuals with phenylketonuria: early signs of treatment discontinuation. *Mol Genet Metab Rep*. 2017;28:54-58.
7. Pena MJ, Almeida MF, van Dam E, et al. Special low protein foods for phenylketonuria: availability in Europe and an examination of their nutritional profile. *Orphanet J Rare Dis*. 2015;10:162.
8. Feinberg SB, Fisch RO. Roentgenologic findings in growing long bones in phenylketonuria. *Preliminary Study*. 1962;78:394-398.
9. Murdoch MM, Holman GH. Roentgenologic bone changes in phenylketonuria. *Relationship to dietary phenylalanine deficiency*. 1964;107:523-532.
10. Porta F, Spada M, Lala R, Mussa A. Phalangeal quantitative ultrasound in children with phenylketonuria: a pilot study. *Ultrasound Med Biol*. 2008;34:1049-1052.
11. Schwahn B, Mokov E, Scheidhauer K, Lettgen B, Schönau E. Decreased trabecular bone mineral density in patients with phenylketonuria measured by peripheral quantitative computed tomography. *Acta Paediatr*. 1998;87:61-63.
12. Zeman J, Bayer M, Stepán J. Bone mineral density in patients with phenylketonuria. *Acta Paediatr*. 1999;88:1348-1351.
13. Allen JR, Humphries IR, Waters DL, et al. Decreased bone mineral density in children with phenylketonuria. *Am J Clin Nutr*. 1994;59:419-422.
14. Coakley KE, Douglas TD, Goodman M, Ramakrishnan U, Dobrowolski SF, Singh RH. Modeling correlates of low bone mineral density in patients with phenylalanine hydroxylase deficiency. *J Inherit Metab Dis*. 2016;39:363-372.
15. Demirdas S, Coakley KE, Bisschop PH, Hollak CE, Bosch AM, Singh RH. Bone health in phenylketonuria: a systematic review and meta-analysis. *Orphanet J Rare Dis*. 2015;15(10):17.

16. Stroup BM, Hansen KE, Krueger D, Binkley N, Ney DM. Sex differences in body composition and bone mineral density in phenylketonuria: a cross-sectional study. *Mol Genet Metab Rep.* 2018;15:30-35.

17. Hansen KE, Ney D. A systematic review of bone mineral density and fractures in phenylketonuria. *J Inherit Metab Dis.* 2014;37:875-880.

18. Ghaloul-Gonzalez L, Mohsen AW, Karunanidhi A, et al. Reticular dysgenesis and Mitochondriopathy induced by adenylate kinase 2 deficiency with atypical presentation. *Sci Rep.* 2019;9:15739.

19. de Groot MJ, Hoeksma M, van Rijn M, Slart RH, van Spronsen FJ. Relationships between lumbar bone mineral density and biochemical parameters in phenylketonuria patients. *Mol Genet Metab.* 2012;105:566-570.

20. Lage S, Bueno M, Andrade F, et al. Fatty acid profile in patients with phenylketonuria and its relationship with bone mineral density. *J Inherit Metab Dis.* 2010;33(Suppl 3):S363-S371.

21. Zeman J, Bayer M, Stepán J. Bone mineral density in patients with phenylketonuria. *Acta Paediatr.* 1999;88:1348-1351.

22. Allen JR, Humphries IR, Waters DL, et al. Decreased bone mineral density in children with phenylketonuria. *Am J Clin Nutr.* 1994;59:419-422.

23. Dobrowolski SF, Sudano C, Phua YL, et al. Mesenchymal stem cell energy deficit and oxidative stress contribute to osteopenia in the Pahenu2 classical PKU mouse. *Mol Genet Metab.* 2021;132:173-179.

24. Dobrowolski SF, Tourkova IL, Robinson LJ, Secunda C, Spridik K, Blair HC. A bone mineralization defect in the Pahenu2 model of classical phenylketonuria involves compromised mesenchymal stem cell differentiation. *Mol Genet Metab.* 2018;125:193-199.

25. Dobrowolski SF, Tourkova IL, Blair HC. PKU osteopenia involves a mesenchymal stem cell developmental defect. *Mol Genet Metab.* 2019;126:296.

26. Zhou T, Yang Y, Chen Q, Xie L. Glutamine metabolism is essential for Stemness of bone marrow mesenchymal stem cells and bone homeostasis. *Stem Cells Int.* 2019;2019(12):8928934.

27. Yu Y, Newman H, Shen L, et al. Glutamine metabolism regulates proliferation and lineage allocation in skeletal stem cells. *Cell Metab.* 2019;2:966-978.

28. Tohyama S, Fujita J, Hishiki T, et al. Glutamine oxidation is indispensable for survival of human pluripotent stem cells. *Cell Metab.* 2016;12:663-674.

29. Stegen S, Devignes CS, Torrekens S, Van Looveren R, Carmeliet P, Carmeliet G. Glutamine metabolism in Osteoprogenitors is required for bone mass accrual and PTH-induced bone anabolism in male mice. *J Bone Miner Res.* 2021;36:604-616.

30. Dobrowolski SF, Lyons-Weiler J, Spridik K, Vockley J, Skvorak K, Biery A. DNA methylation in the pathophysiology of hyperphenylalaninemia in the PAHenu2 mouse model of phenylketonuria. *Mol Genet Metab.* 2016;S1096-7192(16):1-4.

31. Tourkova IL, Liu L, Sutjarit N, et al. Adrenocorticotropic hormone and 1,25-dihydroxyvitamin D3 enhance human osteogenesis in vitro by synergistically accelerating the expression of bone-specific genes. *Lab Invest.* 2017;97:1072-1083.

32. Ghaloul-Gonzalez I, Mohsen AW, Karunanidhi A, et al. Reticular dysgenesis and Mitochondriopathy induced by adenylate kinase 2 deficiency with atypical presentation. *Sci Rep.* 2019;9:15739.

33. Dobrowolski SF, Alodaib A, Karunanidhi A, et al. Clinical, biochemical, mitochondrial, and metabolomic aspects of methylmalonate semialdehyde dehydrogenase deficiency: report of a fifth case. *Mol Genet Metab.* 2020;129:272-277.

34. Dobrowolski SF, Phua YL, Sudano C, et al. Comparative metabolomics in the Pah™ classical PKU mouse identifies cerebral energy pathway disruption and oxidative stress. *Mol Genet Metab.* 2022;136:35-45.

35. Halestrap AP. The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors. *Biochem J.* 1975;148:85-96.

36. Patel MS, Grover WD, Auerbach VH. Pyruvate metabolism by homogenates of human brain: effects of phenylpyruvate and implications for the etiology of the mental retardation in phenylketonuria. *J Neurochem.* 1973;20:289-296.

37. Weber G. Inhibition of human brain pyruvate kinase and hexokinase by phenylalanine and phenylpyruvate: possible relevance to phenylketonic brain damage. *Proc Natl Acad Sci U S A.* 1969;63:1365-1369.

38. Patel MS, Arinze U. Phenylketonuria: metabolic alterations induced by phenylalanine and phenylpyruvate. *Am J Clin Nutr.* 1975;28:183-188.

39. Dobrowolski SF, Phua YL, Vockley J, Goetzman E, Blair HC. Phenylketonuria oxidative stress and energy dysregulation: emerging pathophysiological elements provide interventional opportunity. *Mol Genet Metab.* 2022;S1096-7192(22):282-287.

How to cite this article: Dobrowolski SF, Phua YL, Tourkova IL, et al. Glutamine energy substrate anaplerosis increases bone density in the Pah™ classical PKU mouse in the absence of phenylalanine restriction. *JIMD Reports.* 2022;63(5):446-452. doi:10.1002/jmd2.12308